Obsessive–compulsive disorder

What's Wrong Wellness: One Mother's Chilling Medical Discovery That Could Be Impacting Many Families

Retrieved on: 
Thursday, September 30, 2021

When Elizabeth Harris' son suddenly began exhibiting signs of Obsessive-Compulsive Disorder and other strange behaviors, she was determined to get to the bottom of the cause.

Key Points: 
  • When Elizabeth Harris' son suddenly began exhibiting signs of Obsessive-Compulsive Disorder and other strange behaviors, she was determined to get to the bottom of the cause.
  • This mother of four spends much of her time educating medical professionals and other parents on her discoveries.
  • She resides in Franklin, Tennessee, where she owns What's Wrong Wellness which provides alternative options forchildren in need.You can Pre-Order now from www.whatswrongwellness.com/pre-order .
  • What's Wrong With My Child9781631954979has 252 pages and is being sold as a trade paperback for $17.95.

Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Mental Health Crisis

Retrieved on: 
Thursday, July 15, 2021

The diversified venture fund is focused on tackling the growing global mental health crisis by investing in innovative psychedelic-based and adjacent therapies that are poised to shape the future of psychiatry and fields beyond.

Key Points: 
  • The diversified venture fund is focused on tackling the growing global mental health crisis by investing in innovative psychedelic-based and adjacent therapies that are poised to shape the future of psychiatry and fields beyond.
  • Supported by a rapidly growing body of evidence and strong FDA support, psychedelic-assisted treatments represent a paradigm shift in mental healthcare.
  • Palo Santo is the leading U.S.-based psychedelic investment fund focused on increasing the supply of clinically effective and accessible mental health and addiction treatment solutions needed in today's world.
  • The firm targets a diverse range of companies offering innovative solutions across biopharma, drug development, digital therapeutics, healthcare services, and tech-enabled solutions to address the growing global mental health crisis.

MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

Retrieved on: 
Tuesday, July 13, 2021

The event will feature an opportunity for local mental health providers in the Charlotte area to meet the MindPath Care Center staff and watch live demonstrations of BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) treatment offerings for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).

Key Points: 
  • The event will feature an opportunity for local mental health providers in the Charlotte area to meet the MindPath Care Center staff and watch live demonstrations of BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) treatment offerings for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
  • Because Deep TMS penetrates deeper and broader in the brain than traditional TMS, there is evidence that response rates are higher than traditional TMS.
  • For more information regarding Deep TMS services at MindPath Care Centers, visit www.mindpathcare.com/TMS or call the clinic at 877-876-3783.
  • Community Psychiatry and MindPath Care Centers have combined to expand patient access to high-quality, evidence-based, outpatient mental health care across the United States.

Helping young Canadians get their health back on track after more than a year of COVID-19 pandemic lockdown

Retrieved on: 
Thursday, July 8, 2021

Helping teens get their mental health and well-being back on track after more than a year of COVID-19 pandemic lockdown.

Key Points: 
  • Helping teens get their mental health and well-being back on track after more than a year of COVID-19 pandemic lockdown.
  • Quashis a free, made-in-Canada app based on behaviour change science to help teens quit their way, free of the judgement that can often lead to setbacks.
  • A recent study shows that during the pandemic, about 70 per cent of youth ages six to 18 experienced depression, anxiety, irritability, a lower attention span, or obsessions and compulsions.
  • The Lung Health Foundation is the leading national charity dedicated to improving the lung health of Canadians.

Ketamine One Launches Immersive Virtual Reality R&D Program at MindScape Clinic

Retrieved on: 
Monday, June 7, 2021

Clinic patients who select IVR-based treatments will receive a tailored therapy plan that includes a determination of their mental state and individual goals.

Key Points: 
  • Clinic patients who select IVR-based treatments will receive a tailored therapy plan that includes a determination of their mental state and individual goals.
  • With over 2,000 treatments administered since inception, MindScape also recently expanded its service offering to provide spa-like therapeutic treatment experiences.
  • Mindscape Ketamine & Infusions Therapy, PLLC is a clinic in Houston, Texas, offering affordable delivery of concierge IV ketamine therapy for treatment-resistant mood disorders, mental health disorders, and chronic pain conditions.
  • Mindscape Ketamine & Infusion Therapy, PLLC is the only IV ketamine clinic in Houston to offer virtual reality-based guided meditation to complement IV ketamine infusions in the treatment of depression, bipolar disorder, anxiety, PTSD, OCD, and other mood disorders.

‘Hidden’ OCD Population Costing Payers, Employers Billions Annually

Retrieved on: 
Friday, June 4, 2021

They are hidden, or submerged, within the member population as a result of being unidentified or misdiagnosed.

Key Points: 
  • They are hidden, or submerged, within the member population as a result of being unidentified or misdiagnosed.
  • This indicates 96% of the OCD population in the sample is not being treated for OCD as a primary diagnosis.
  • We help people reclaim their lives with clinically proven OCD treatment, by removing barriers to OCD care, and by reducing the stigma associated with OCD.
  • Working together with our therapists, patients, health plans, providers, and employers, we are improving the lives of people with OCD.

BrainsWay Announces First Draft Proposal for OCD Coverage by a Regional Medicare Administrative Contractor

Retrieved on: 
Tuesday, June 1, 2021

The BrainsWay team has worked closely with the MACs, and specifically Palmetto, to provide the appropriate published clinical literature for Deep TMS in support of this proposed draft LCD.

Key Points: 
  • The BrainsWay team has worked closely with the MACs, and specifically Palmetto, to provide the appropriate published clinical literature for Deep TMS in support of this proposed draft LCD.
  • We look forward to the formal policy from Palmetto, and anticipate that other MACs, over time, will also issue their draft policies for Deep TMS coverage of OCD.
  • We remain committed to working to secure further coverage policy decisions from additional payors in the coming months.
  • The patient selection criteria identified in Palmettos draft LCD is closely aligned with the Clinical TMS Societys recommended OCD coverage policy.

BrainsWay Announces First of its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS™

Retrieved on: 
Monday, May 24, 2021

Centenes new policy specifies that coverage will be exclusive for the treatment of OCD utilizing Deep TMS, which is a form of therapy solely associated with BrainsWays patented H-Coil technology.

Key Points: 
  • Centenes new policy specifies that coverage will be exclusive for the treatment of OCD utilizing Deep TMS, which is a form of therapy solely associated with BrainsWays patented H-Coil technology.
  • BrainsWays H7-Coil is designed to penetrate deeper and more medial to stimulate the structures of the brain associated with OCD.
  • The establishment of this positive Deep TMS coverage policy is the first of its kind for OCD in the broader TMS space.
  • This positive coverage decision reflects the large body of compelling clinical evidence supporting the treatment of OCD with our Deep TMS H7-Coil, further differentiating it from traditional TMS coils.

Decluttering the Family "Attic"--Metaphorically Speaking (Pandemic Edition)

Retrieved on: 
Wednesday, May 19, 2021

Our relationship profited alongside Home Depot\'s and Lowe\'s pandemic profits .\nLike many, we began with decluttering not for self-improvement with decluttering-guru guides to making lemonade out of pandemic lemons, but in a what-the-heck spirit.\nThe decluttering process brought pain.

Key Points: 
  • Our relationship profited alongside Home Depot\'s and Lowe\'s pandemic profits .\nLike many, we began with decluttering not for self-improvement with decluttering-guru guides to making lemonade out of pandemic lemons, but in a what-the-heck spirit.\nThe decluttering process brought pain.
  • Not the pain of obsessing over what physical stuff to toss, but rather the emotional pain that can get triggered by some of the physical stuff.
  • Then we can consciously decide which patterns to replicate with pleasure, toss, or treasure but not use (my great-grandma\'s teapot).
  • For interviews with Dr. Held, contact Doug Cook, director of college and media relations, [email protected] .\n'

NOCD Funds Actuarial Study to Reveal Social, Clinical, and Financial Impact of OCD

Retrieved on: 
Monday, May 10, 2021

Interested parties should register for the event now and plan to attend the session titled OCD Prevalence and Outcomes.

Key Points: 
  • Interested parties should register for the event now and plan to attend the session titled OCD Prevalence and Outcomes.
  • We help people reclaim their lives with clinically proven OCD treatment, by removing barriers to OCD care, and by reducing the stigma associated with OCD.
  • Working together with our therapists, patients, health plans, providers, and employers, we are improving the lives of people with OCD.
  • Please visit our website for more information about NOCD.\n* Certain data used in this study were supplied by International Business Machines Corporation (IBM).